225Ac-PSMA-671 TAT showed promising anti-tumor activity, sustained response and low treatment-related toxicities. Currently, at our department of Nuclear Medicine, the above promising results led to the commencement of an ongoing phase II clinical trial to validated the above findings.Chandrasekhar ...
Overall, administration of 225Ac-PSMA-617 was well tolerated. The commonest toxicity seen was grade I/II dry mouth observed in 94% of patients. Conclusions Given these favorable results, randomized prospective multicenter trials assessing the clinical value of 225Ac-PSMA-617 as a therapeutic agent...
225Ac-PSMA-617 for PSMA-targeted alpha- radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4. https://doi.org/ 10.2967/jnumed.116.178673. Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy...
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol. (2018) S. Nilsson et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, ...
First clinical experience with 225Ac-PSMA-617 demonstrates promising antitumor activity with a 63%-70% PSA>50%-response rate, 10-15 months duration of response and complete remissions in approximately ten percent of patients, some of them with enduring relapse-free survival. Nevertheless, without ...
(SOC) or with SOC alone. The primary objective of this trial was to compare the radiological progression-free survival (PFS) and overall survival (OS) in the two treatment arms. Patients treated with177Lu-PSMA received [177Lu]Lu-PSMA-617 every six weeks for at least four cycles (up to ...
Over the past two decades, PRRT has expanded its clinical utility by delivering radiation directly to cancer cells at the cellular level through an SSTR ligand chelated to a radioisotope, causing irreversible damage to cancer cell DNA and inducing apoptosis. Initially utilizing beta-emitting ...
TPS282#Background:Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatment modality for prostate cancer. First-generation PSMA-targeting ligands (e.g., PSMA-617 and PSMA-I&T) paired with Ac-225 have been ...
Results: Seventy one patients were treated with a total of 155 cycles, of which 5 received 225Ac-PSMA-617, while the rest received 177Lu-PSMA-617 radioligand therapy. The primary objective was a PSA response. We found a significant PSA response with 46.5% of patients demonstrating a greater...
Part 2 (P2) randomizes 1:1 between 45 and 60 kBq/kg in patients with CRPC without prior exposure to Lu-177-PSMA (-617 or -I&T). Part 3 (P3) is a Bayesian Optimal Interval (BOIN) design dose-escalation protocol (45, 55, and 60 kBq/kg, with optional dose expansion) for ...